<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533613487218</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533613487218</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of Exclusive Enteral Nutrition on Health-Related Quality of Life for Adults With Active Crohn’s Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Guo</surname><given-names>Zhen</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Rong</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhu</surname><given-names>Weiming</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Gong</surname><given-names>Jianfeng</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Wei</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Yi</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Gu</surname><given-names>Lili</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Ning</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Jieshou</given-names></name>
<degrees>MD</degrees>
</contrib>
<aff id="aff1-0884533613487218">Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, PR China</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0884533613487218">Weiming Zhu, Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No. 305 East Zhongshan Rd, Nanjing 210002, People’s Republic of China. Email: <email>drweimingzhu@126.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>499</fpage>
<lpage>505</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Exclusive enteral nutrition (EEN) is an effective and safe remission induction treatment for Crohn’s disease in adults. Its influence on adults’ health-related quality of life remains unknown. The aim of this study was to determine the effect of EEN on health-related quality of life in adults with active Crohn’s disease. <italic>Materials and Methods</italic>: Patients recruited were treated with a polymeric enteral feed that was taken orally in the daytime and via a self-intubated nasogastric tube at night for 4 weeks. Prospective evaluation of disease activity (Crohn’s Disease Activity Index, CDAI) and health-related quality of life (Inflammatory Bowel Disease Questionnaire, IBDQ) were performed at enrollment and after 4 weeks of treatment. Patients’ feelings about EEN were also investigated through 2 questions. <italic>Results</italic>: Thirteen patients were treated with 4-week EEN. They had a significant improvement in total IBDQ score (<italic>P</italic> &lt; .001) and all IBDQ dimensions: bowel symptoms (<italic>P</italic> &lt; .001), systemic symptoms (<italic>P</italic> &lt; .001), social function (<italic>P</italic> = .003), and emotional status (<italic>P</italic> &lt; .001), with 11 patients (84.6%) achieving clinical remission after treatment. In addition, 8 patients (61.5%) expressed their willingness to receive this 4-week EEN treatment again to induce remission if the disease relapsed. The IBDQ correlated significantly with the CDAI at 4 weeks. <italic>Conclusions</italic>: A 4-week treatment of EEN improves health-related quality of life significantly in adults with active Crohn’s disease and was acceptable by most patients.</p>
</abstract>
<kwd-group>
<kwd>Crohns disease</kwd>
<kwd>enteral nutrition</kwd>
<kwd>quality of life</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Crohn’s disease (CD) is a chronic inflammatory transmural gastrointestinal (GI) disorder characterized by abdominal symptoms, malnutrition, extraintestinal manifestations, and some adverse events of treatments such as immunosuppressive drugs and surgery. These potential symptoms and complications increase patients’ stress levels and negatively affect physical, social, and psychological functioning, which have been proved to decrease patients’ health-related quality of life (HRQOL).<sup><xref ref-type="bibr" rid="bibr1-0884533613487218">1</xref><xref ref-type="bibr" rid="bibr2-0884533613487218"/>-<xref ref-type="bibr" rid="bibr3-0884533613487218">3</xref></sup> In the current medical treatment of CD, managing HRQOL is increasingly becoming an essential consideration.</p>
<p>Exclusive enteral nutrition (EEN) has shown to be an effective and safe therapeutic option for inducing remission of CD in adults.<sup><xref ref-type="bibr" rid="bibr4-0884533613487218">4</xref>,<xref ref-type="bibr" rid="bibr5-0884533613487218">5</xref></sup> Although a meta-analysis concluded that corticosteroids were more effective in inducing remission than EEN,<sup><xref ref-type="bibr" rid="bibr6-0884533613487218">6</xref></sup> low rates of mucosal healing, steroid dependency, increased risk of infection, and other adverse effects limit the use of corticosteroids.<sup><xref ref-type="bibr" rid="bibr7-0884533613487218">7</xref></sup> In addition to inducing clinical remission, EEN has other advantages such as improving nutrition status, safety even with long-term use, and enhanced mucosal healing compared with corticosteroids.<sup><xref ref-type="bibr" rid="bibr8-0884533613487218">8</xref></sup> But EEN has been considered not applicable for most adult patients with CD because of palatability of feeds, having to stay on a solid-free diet for weeks, and social inconvenience, which may reduce patients’ HRQOL.<sup><xref ref-type="bibr" rid="bibr9-0884533613487218">9</xref></sup></p>
<p>The influence of enteral nutrition (EN) on HRQOL was shown in 2 clinical trials of patients with CD. In a randomized controlled trial in Japan, the Inflammatory Bowel Disease Questionnaire (IBDQ) score was not significantly different between the half-elemental diet group and the free diet group.<sup><xref ref-type="bibr" rid="bibr10-0884533613487218">10</xref></sup> In another trial, Afzal et al<sup><xref ref-type="bibr" rid="bibr11-0884533613487218">11</xref></sup> confirmed a clear improvement in HRQOL after treatment with EEN in children with active CD. However, it remains undocumented whether treatment with EEN also leads to an improved HRQOL in adults with active CD. The purpose of this nonrandomized trial is to evaluate the effect of EEN on the HRQOL of adults with active CD. We also assessed the relationship between IBDQ scores and Crohn’s Disease Activity Index (CDAI) scores.</p>
<sec id="section1-0884533613487218" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section2-0884533613487218">
<title>Patients</title>
<p>This was an uncontrolled pilot clinical trial. Patients satisfying the following criteria were consecutively recruited between August 2011 and August 2012: (1) patients within the age range of 18–40 years; (2) patients who had clinical, imaging, endoscopic, and histologic diagnosis of CD; (3) patients who had a CDAI score of &gt;150 and &lt;400; and (4) those who had a C-reactive protein (CRP) level of &gt;10 mg/L at enrollment.<sup><xref ref-type="bibr" rid="bibr12-0884533613487218">12</xref></sup> Patients meeting the following criteria were excluded from this study: (1) patients who presented with intestinal obstruction, (2) patients who had bowel resection for CD, and (3) those who received corticosteroids, immunosuppressive drugs, or biological therapy in the past 3 months. Patients who received stable treatment of sulfasalazine or mesalazine for more than 1 month were included, with the dose unchanged during the entire study. Patients who needed immunosuppressive drugs or surgeries during the study were excluded. This study was approved by the Institutional Ethics Committee of our hospital.</p>
</sec>
<sec id="section3-0884533613487218">
<title>Treatment</title>
<p>Patients included were treated with EEN. Any other food and drink except water was forbidden. Polymeric formula (<xref ref-type="table" rid="table1-0884533613487218">Table 1</xref>) was used in this study, because the type of formula makes no difference to the efficacy in inducing remission, and the polymeric formula is more palatable and less expensive than the elemental formula.<sup><xref ref-type="bibr" rid="bibr13-0884533613487218">13</xref></sup> Patients took the multiple low-dose EN suspension orally in the daytime, with the rest accomplished through a self-intubated nasogastric tube at night. The daily calorie intake was 25–30 kcal/kg body weight and was gradually increased from half that amount to the full amount over 2 days. The formula had 500 kcal/bottle. To facilitate the operation for patients, the actual intake was 1500 kcal/d or 2000 kcal/d. By doing this, in this trial, most patients’ daily calorie intake was 25–30 kcal/kg; only 1 patient’s intake was 30–35 kcal/kg. The calorie intake of the oral daily drinks and the nighttime feeding was adjusted by the patients themselves. We followed up each patient every week by telephone or interview, and the patients could contact us when they had trouble.</p>
<table-wrap id="table1-0884533613487218" position="float">
<label>Table 1.</label>
<caption>
<p>Composition of the Formula.</p>
</caption>
<graphic alternate-form-of="table1-0884533613487218" xlink:href="10.1177_0884533613487218-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Per 500 mL<hr/></th>
</tr>
<tr>
<th align="center">Ingredient</th>
<th align="center">Content</th>
<th align="center">Ingredient</th>
<th align="center">Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Calorie</td>
<td>500 mL (500 kcal)</td>
<td>Fe</td>
<td>8 mg</td>
</tr>
<tr>
<td>Protein</td>
<td>20 g (80 kcal)</td>
<td>Zn</td>
<td>6 mg</td>
</tr>
<tr>
<td> N</td>
<td>3.15 g</td>
<td>Cu</td>
<td>900 µg</td>
</tr>
<tr>
<td> NPC:N</td>
<td>133:1</td>
<td>Mn</td>
<td>1650 µg</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>61.5 g (245 kcal)</td>
<td>F</td>
<td>0.5 mg</td>
</tr>
<tr>
<td> Glucose</td>
<td>5.0 g</td>
<td>Se</td>
<td>28.5 µg</td>
</tr>
<tr>
<td> Polycose</td>
<td>55.5 g</td>
<td>Cr</td>
<td>33.4 µg</td>
</tr>
<tr>
<td> Lactose</td>
<td>&lt;0.125 g</td>
<td>Vitamin A</td>
<td>410 µg</td>
</tr>
<tr>
<td>Lipid</td>
<td>19.45 g (176 kcal)</td>
<td>Vitamin D</td>
<td>3.5 µg</td>
</tr>
<tr>
<td> Saturated fat</td>
<td>1.45 g</td>
<td>Vitamin E</td>
<td>6.5 α-TE</td>
</tr>
<tr>
<td> Polyunsaturated fat</td>
<td>6.15 g</td>
<td>Vitamin K</td>
<td>26.5 µg</td>
</tr>
<tr>
<td>Dietary fiber</td>
<td>7.5 g</td>
<td>Choline</td>
<td>185 mg</td>
</tr>
<tr>
<td>Water</td>
<td>425 g</td>
<td>Folic acid</td>
<td>133.5 µg</td>
</tr>
<tr>
<td>Na</td>
<td>500 mg</td>
<td>Vitamin C</td>
<td>50 mg</td>
</tr>
<tr>
<td>K</td>
<td>750 mg</td>
<td>Niacin</td>
<td>9 mg</td>
</tr>
<tr>
<td>Cl</td>
<td>625 mg</td>
<td>Biotin</td>
<td>20 µg</td>
</tr>
<tr>
<td>Ca</td>
<td>400 mg</td>
<td>Carotenoid</td>
<td>1.0 mg</td>
</tr>
<tr>
<td>P</td>
<td>360 mg</td>
<td>Mg</td>
<td>115 mg</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533613487218">
<p>Ca, calcium; Cl, chloride; Cr, chromium; Cu, copper; F, fluorine; Fe, iron; K, potassium; Mg, magnesium; Mn, manganese; N, nitrogen; Na, sodium; NPC, nonprotein calorie; P, phosphorus; Se, selenium; Zn, zinc.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0884533613487218">
<title>HRQOL Assessment</title>
<p>We assessed HRQOL by using the IBDQ, which was adequately translated into Chinese. The IBDQ is a widely used assessment tool to evaluate treatment effects on HRQOL in CD, and its reliability, validity, and responsiveness have been confirmed.<sup><xref ref-type="bibr" rid="bibr14-0884533613487218">14</xref></sup> The IBDQ covers 4 major HRQOL dimensions (ie, bowel symptoms, systemic symptoms, social function, and emotional status) and consists of 32 questions.<sup><xref ref-type="bibr" rid="bibr15-0884533613487218">15</xref></sup> The total score ranges from 32–224, with higher scores representing better HRQOL.<sup><xref ref-type="bibr" rid="bibr16-0884533613487218">16</xref></sup> For each patient, HRQOL was evaluated at baseline and after the treatment.</p>
<p>At the end of the treatment, each patient was asked the following questions to investigate patients’ feelings toward a 4-week treatment of EEN:</p>
<list id="list1-0884533613487218" list-type="order">
<list-item><p>Would you like to receive EEN for a longer time? Yes or no.</p></list-item>
<list-item><p>Would you like to receive the same treatment to induce remission when the disease relapses? Yes or no.</p></list-item>
</list>
</sec>
<sec id="section5-0884533613487218">
<title>Clinical Assessment</title>
<p>Clinical assessment was conducted once every 2 weeks during the study period. The CDAI score and body mass index (BMI) were calculated. CRP level, erythrocyte sedimentation rate (ESR), white blood cell count, hemoglobin, and serum albumin level of peripheral venous blood samples were measured every 2 weeks.</p>
</sec>
<sec id="section6-0884533613487218">
<title>Definition of Clinical Outcome</title>
<p>Clinical remission was defined as a CDAI score &lt;150 points and CRP level &lt;10 mg/L. An IBDQ score &gt;170 was considered consistent with clinical remission and an increase of &gt;16 a clinically meaningful improvement.<sup><xref ref-type="bibr" rid="bibr17-0884533613487218">17</xref></sup></p>
</sec>
<sec id="section7-0884533613487218">
<title>Statistical Analysis</title>
<p>Statistical analysis was carried out with SPSS version 17.0 (SPSS, Inc, an IBM Company, Chicago, IL). The outcome before and after treatment was compared using the paired <italic>t</italic> test. A regression model was used to explore the relationship between HRQOL and CDAI. <italic>P</italic> &lt; .05 was considered significant.</p>
</sec>
</sec>
<sec id="section8-0884533613487218" sec-type="results">
<title>Results</title>
<sec id="section9-0884533613487218">
<title>Patients’ Baseline Characteristics</title>
<p>Fifteen patients were enrolled in this study. Two patients were excluded, one because he doubted that EEN would have a beneficial effect on inducing remission and the other because of the appearance of intestinal obstruction during treatment. Patients’ demographic details are shown in <xref ref-type="table" rid="table2-0884533613487218">Table 2</xref>.</p>
<table-wrap id="table2-0884533613487218" position="float">
<label>Table 2.</label>
<caption>
<p>Patients’ Baseline Characteristics (n = 13).</p>
</caption>
<graphic alternate-form-of="table2-0884533613487218" xlink:href="10.1177_0884533613487218-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Patient Characteristics</th>
<th align="center">Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female sex, No.</td>
<td>9/4</td>
</tr>
<tr>
<td>Age, y, mean (SD)</td>
<td>26.1 (3.8)</td>
</tr>
<tr>
<td>Duration of disease, mo, mean (SD)</td>
<td>17.0 (11.6)</td>
</tr>
<tr>
<td colspan="2">Type of disease, No.</td>
</tr>
<tr>
<td> Ileitis</td>
<td>2</td>
</tr>
<tr>
<td> Ileocolitis</td>
<td>10</td>
</tr>
<tr>
<td> Colitis</td>
<td>1</td>
</tr>
<tr>
<td>Smokers, No.</td>
<td>0</td>
</tr>
<tr>
<td>Concomitant medication (5-ASA), No.</td>
<td>9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0884533613487218">
<p>5-ASA, 5-aminosalicylic acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0884533613487218">
<title>Clinical Response to EEN</title>
<p>All 13 patients were compliant, and EEN was well tolerated. Eleven patients (84.6%) achieved clinical remission after 4 weeks of treatment, and 2 (15.4%) patients had no response. The mean ± SD CDAI score and CRP level were 232.2 ± 49.8 and 34.6 ± 23.7 before treatment and 84.7 ± 39.3 (<italic>P</italic> &lt; .001) and 4.0 ± 2.4 (<italic>P</italic> = .001) after treatment.</p>
<p>The CDAI consists of 8 factors, each summed after adjustment with a weighting factor. Among these factors, the score for the number of liquid or soft stools, abdominal pain, general well-being, and percentage deviation from standard weight descended significantly after the 4 weeks of treatment (<italic>P</italic> &lt; .05), whereas no difference was found in the score for the presence of complications, taking Atropine/diphenoxylate or opiates, presence of an abdominal mass, and hematocrit (<xref ref-type="table" rid="table3-0884533613487218">Table 3</xref>).</p>
<table-wrap id="table3-0884533613487218" position="float">
<label>Table 3.</label>
<caption>
<p>Comparative Scores Before and After Treatment With EEN.</p>
</caption>
<graphic alternate-form-of="table3-0884533613487218" xlink:href="10.1177_0884533613487218-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">Before EEN, Mean (SD)</th>
<th align="center">After EEN, Mean (SD)</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Normal Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDAI</td>
<td>232.2 (49.8)</td>
<td>84.7 (39.3)</td>
<td>&lt;.001</td>
<td>&lt;150</td>
</tr>
<tr>
<td> Liquid or soft stools</td>
<td>44.9 (16.2)</td>
<td>9.2 (15.5)</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td> Abdominal pain</td>
<td>57.2 (20.4)</td>
<td>6.5 (12.6)</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td> General well-being</td>
<td>62.3 (36.0)</td>
<td>8.8 (9.0)</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td> Presence of complications<sup><xref ref-type="table-fn" rid="table-fn4-0884533613487218">a</xref></sup></td>
<td>4.6 (8.8)</td>
<td>0 (0)</td>
<td>.082</td>
<td/>
</tr>
<tr>
<td> Atropine/diphenoxylate or opiates</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td/>
<td/>
</tr>
<tr>
<td> Abdominal mass<sup><xref ref-type="table-fn" rid="table-fn5-0884533613487218">b</xref></sup></td>
<td>1.5 (5.5)</td>
<td>1.5 (5.5)</td>
<td/>
<td/>
</tr>
<tr>
<td> Hematocrit</td>
<td>42.5 (16.9)</td>
<td>41.0 (13.3)</td>
<td>.658</td>
<td/>
</tr>
<tr>
<td> Weight</td>
<td>20.7 (9.1)</td>
<td>18.6 (9.2)</td>
<td>.006</td>
<td/>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>34.6 (23.7)</td>
<td>4.0 (2.4)</td>
<td>.001</td>
<td>&lt;10</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>31.3 (15.7)</td>
<td>12.3 (5.0)</td>
<td>&lt;.001</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Serum albumin, g/L</td>
<td>39.4 (3.4)</td>
<td>42.2 (3.0)</td>
<td>.018</td>
<td>35.0–55.0</td>
</tr>
<tr>
<td>BMI</td>
<td>18.1 (2.2)</td>
<td>18.7 (1.8)</td>
<td>.014</td>
<td>18.5–23.9</td>
</tr>
<tr>
<td>Total IBDQ score</td>
<td>128.3 (15.8)</td>
<td>182.9 (24.2)</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td> Bowel symptoms</td>
<td>41.5 (4.6)</td>
<td>62.0 (8.1)</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td> Systemic symptoms</td>
<td>16.5 (2.9)</td>
<td>27.5 (4.6)</td>
<td>&lt;.001</td>
<td/>
</tr>
<tr>
<td> Social function</td>
<td>20.5 (4.5)</td>
<td>26.5 (4.7)</td>
<td>.003</td>
<td/>
</tr>
<tr>
<td> Emotional status</td>
<td>49.8 (8.8)</td>
<td>66.9 (9.8)</td>
<td>&lt;.001</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0884533613487218">
<p>BMI, body mass index; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; EEN, exclusive enteral nutrition; ESR, erythrocyte sedimentation rate; IBDQ, Inflammatory Bowel Disease Questionnaire.</p>
</fn>
<fn id="table-fn4-0884533613487218">
<label>a</label>
<p>One patient with fever; 2 patients with aphthous ulcers.</p>
</fn>
<fn id="table-fn5-0884533613487218">
<label>b</label>
<p>One patient with a questionable mass.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-0884533613487218">
<title>Heath-Related Quality of Life</title>
<p>At enrollment, all patients’ HRQOL was poor (IBDQ score &lt;170). There were significant improvements in total IBDQ scores after the 4-week EEN treatment (mean ± SD, 128.3 ± 15.8 to 182.9 ± 24.2, <italic>P</italic> &lt; .001). Ten patients (76.9%) achieved an IBDQ total score &gt;170, whereas 3 (23.1%) patients had no meaningful changes. Evaluation of each dimension indicated a significant improvement in all categories: bowel symptoms (mean ± SD, 41.5 ± 4.6 to 62.0 ± 8.1, <italic>P</italic> &lt; .001), systemic symptoms (16.5 ± 2.9 to 27.5 ± 4.6, <italic>P</italic> &lt; .001), social function (20.5 ± 4.5 to 26.5 ± 4.7, <italic>P</italic> = .03), and emotional status (49.8 ± 8.8 to 66.9 ± 9.8, <italic>P</italic> &lt; .001) (<xref ref-type="fig" rid="fig1-0884533613487218">Figure 1</xref>).</p>
<fig id="fig1-0884533613487218" position="float">
<label>Figure 1.</label>
<caption>
<p>Mean Inflammatory Bowel Disease Questionnaire (IBDQ) score before and after a 4-week treatment of exclusive enteral nutrition.</p>
</caption>
<graphic xlink:href="10.1177_0884533613487218-fig1.tif"/>
</fig>
<p>The total IBDQ score was &gt;170 in 10 of 11 (91%) patients who achieved clinical remission, and the mean change was 62.1 after treatment. In contrast, the mean change was 13.5, and neither of the 2 patients who did not respond to treatment had a clinically meaningful change.</p>
<p>Every patient was asked the 2 questions after the 4-week EEN. Two patients (15.4%) expressed a willingness to receive EEN for a longer time. Eight patients (61.5%) would receive the 4-week EEN treatment again to induce remission when the disease relapses.</p>
</sec>
<sec id="section12-0884533613487218">
<title>Correlation Between HRQOL and CDAI, HRQOL and CRP</title>
<p>There was no correlation between the IBDQ and CDAI before treatment (<italic>r</italic> = −1.17; <italic>P</italic> = .704), but a correlation was noticed after the 4-week treatment (<italic>r</italic> = −0.571; <italic>P</italic> = .042) (<xref ref-type="fig" rid="fig2-0884533613487218">Figure 2</xref>). No correlation was observed between HRQOL and CRP both before and after treatment.</p>
<fig id="fig2-0884533613487218" position="float">
<label>Figure 2.</label>
<caption>
<p>Linear correlation between the Inflammatory Bowel Disease Questionnaire (IBDQ) and Crohn’s Disease Activity Index (CDAI) before and after a 4-week treatment of exclusive enteral nutrition.</p>
</caption>
<graphic xlink:href="10.1177_0884533613487218-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section13-0884533613487218" sec-type="discussion">
<title>Discussion</title>
<p>In this uncontrolled pilot study, we assessed the influence of EEN on HRQOL of adults with active CD by using the IBDQ score along with the efficacy of EEN on inducing clinical remission. While staying on a complete polymeric diet for 4 weeks, patients’ HRQOL improved significantly after EEN treatment with clinical remission in 11 of 13 patients (84.6%). The results also showed that improved HRQOL correlated with the clinical remission.</p>
<p>This study has rates of remission that compare favorably with those (from 41%–85%) reported in other trials using EN for the treatment of active CD.<sup><xref ref-type="bibr" rid="bibr18-0884533613487218">18</xref><xref ref-type="bibr" rid="bibr19-0884533613487218"/><xref ref-type="bibr" rid="bibr20-0884533613487218"/><xref ref-type="bibr" rid="bibr21-0884533613487218"/>-<xref ref-type="bibr" rid="bibr22-0884533613487218">22</xref></sup> This high rate of remission in the current study may be associated with an appropriate regimen for EN, the exclusion of severe disease, and the exclusion of patients who received corticosteroids, immunosuppressive drugs, or biological therapy recently. That none of the patients were smokers also may have contributed to the high rate because smokers are more likely to develop CD and relapses.<sup><xref ref-type="bibr" rid="bibr23-0884533613487218">23</xref>,<xref ref-type="bibr" rid="bibr24-0884533613487218">24</xref></sup> Also, the chance selection of patients who happened to be responders to EEN may be another possible reason.</p>
<p>The management of CD is evolving beyond symptom control. Good HRQOL is one of the ultimate goals.<sup><xref ref-type="bibr" rid="bibr25-0884533613487218">25</xref></sup> Prior studies have noted that EN had a positive impact on HRQOL in adults who were treated with a half-elemental diet for maintenance therapy,<sup><xref ref-type="bibr" rid="bibr10-0884533613487218">10</xref>,<xref ref-type="bibr" rid="bibr26-0884533613487218">26</xref></sup> and children with active CD who were treated with EEN for 8 weeks had a great improvement in HRQOL.<sup><xref ref-type="bibr" rid="bibr11-0884533613487218">11</xref></sup></p>
<p>Despite the disadvantages of EEN, such as complete food avoidance and social inconvenience that may negatively influence patients’ HRQOL, in our study, adults with active CD who were treated with 4-week EEN had a great improvement in the total IBDQ score, and 10 (76.9%) achieved a good HRQOL. They also had significant improvement in all 4 IBDQ dimensions: bowel symptoms, systemic symptoms, social function, and emotional status. The prime reason for improvement in HRQOL was associated with clinical remission. Patients’ HRQOL correlates with the activity of CD.<sup><xref ref-type="bibr" rid="bibr14-0884533613487218">14</xref></sup> Our results also showed that improved HRQOL paralleled the clinical remission. Although there was no correlation between the IBDQ score and CDAI at baseline, a correlation was manifested at 4 weeks. Some factors in the CDAI may be related to this correlation. As shown in the Results section, the score for clinical factors in the CDAI (number of liquid or soft stools, and abdominal pain) changed markedly, which could explain most of the improvements in the IBDQ score, especially in the bowel symptoms dimension. Also, the significantly improved general well-being contributed to the meaningful improvement in the IBDQ score, mainly in the systemic symptoms dimension. In contrast, in this trial, other factors (presence of complications, taking lomotil or opiates, presence of an abdominal mass, and hematocrit) with little or no changes were unlikely to affect the IBDQ score. HRQOL is also determined by personal characteristics, socioeconomic status, number of relapses, and social support.<sup><xref ref-type="bibr" rid="bibr3-0884533613487218">3</xref>,<xref ref-type="bibr" rid="bibr27-0884533613487218">27</xref>,<xref ref-type="bibr" rid="bibr28-0884533613487218">28</xref></sup> This may explain why patients with a similar CDAI had a different IBDQ score at enrollment. Throughout our study, no adverse effect was caused by EEN, which also may have contributed to the improved HRQOL. In addition, the improvement in the taste of the polymeric formula has decreased the negative influence of EEN on HRQOL.<sup><xref ref-type="bibr" rid="bibr29-0884533613487218">29</xref></sup> In this study, all patients were taught to insert the nasogastric tube by themselves. Everyone could master this technique, and no related adverse events happened. Patients also took the EN suspension via a nasogastric tube only at night, which helped avoid the impact of tube feeding on social activities.</p>
<p>The IBDQ lacks a description of patients’ feelings about the treatment and intervention. To investigate patients’ attitude toward EEN, we asked 2 questions. Most patients (84.6%) did not want to receive EEN for a longer time, but more than half (61.5%) expressed their willingness to receive this 4-week EEN treatment again to induce remission. The main obstacle preventing patients from long-term use of EEN was the desire to have a normal diet. According to this result, we reached the tentative conclusion that a 4-week treatment of EEN as an inducing remission therapy was acceptable for patients, but a longer use of EEN may result in patients’ displeasure. Shortening the duration of EEN on the premise that remission can be achieved may be beneficial to patients’ HRQOL.</p>
<p>This study has limitations. First, it was a small study without a control group, which could not negate the placebo effect, and it was not blinded. Such an open-label outcome study is of lower research value than a double-blind placebo trial. Second, it was a single-center trial, and patients were from the same nation. Cultural expectations may influence patients’ IBDQ score, especially the dimensions of social function and emotional status, which may affect the generalizability of the present study. These should be taken into consideration in any future study.</p>
<p>In conclusion, our study showed that a 4-week treatment of EEN as a CD remission induction therapy improved the HRQOL of adults with active CD markedly and was acceptable for most patients. Moreover, the improvement in HRQOL was associated with clinical remission.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This work was supported by funding from the National Ministry of Health for the Digestive Disease (Grant 201002020).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533613487218">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casellas</surname><given-names>F</given-names></name>
<name><surname>López-Vivancos</surname><given-names>J</given-names></name>
<name><surname>Vergara</surname><given-names>M</given-names></name>
<name><surname>Malagelada</surname><given-names>J</given-names></name>
</person-group>. <article-title>Impact of inflammatory bowel disease on health-related quality of life</article-title>. <source>Dig Dis</source>. <year>1999</year>;<volume>17</volume>:<fpage>208</fpage>-<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr2-0884533613487218">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>RD</given-names></name>
</person-group>. <article-title>The quality of life in patients with Crohn’s disease</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2002</year>;<volume>16</volume>:<fpage>1603</fpage>-<lpage>1609</lpage>.</citation>
</ref>
<ref id="bibr3-0884533613487218">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moradkhani</surname><given-names>A</given-names></name>
<name><surname>Beckman</surname><given-names>LJ</given-names></name>
<name><surname>Tabibian</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors</article-title> [published online August 9, 2012]. <source>J Crohns Colitis</source>. doi:<pub-id pub-id-type="doi">10.1016/j.crohns.2012.07.012.</pub-id></citation>
</ref>
<ref id="bibr4-0884533613487218">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindor</surname><given-names>KD</given-names></name>
<name><surname>Fleming</surname><given-names>CR</given-names></name>
<name><surname>Burnes</surname><given-names>JU</given-names></name>
<name><surname>Nelson</surname><given-names>JK</given-names></name>
<name><surname>Ilstrup</surname><given-names>DM</given-names></name>
</person-group>. <article-title>A randomized prospective trial comparing a defined formula diet, corticosteroids and a defined formula diet plus corticosteroids in active Crohn’s disease</article-title>. <source>Mayo Clin Proc</source>. <year>1992</year>;<volume>67</volume>:<fpage>328</fpage>-<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr5-0884533613487218">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorard</surname><given-names>DA</given-names></name>
<name><surname>Hunt</surname><given-names>JG</given-names></name>
<name><surname>Payne-James</surname><given-names>JJ</given-names></name><etal/>
</person-group>. <article-title>Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone</article-title>. <source>Gut</source>. <year>1993</year>;<volume>34</volume>:<fpage>1198</fpage>-<lpage>1202</lpage>.</citation>
</ref>
<ref id="bibr6-0884533613487218">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zachos</surname><given-names>M</given-names></name>
<name><surname>Tondeur</surname><given-names>M</given-names></name>
<name><surname>Griffiths</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Enteral nutritional therapy for induction of remission in Crohn’s disease</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2007</year>;(<issue>1</issue>):<fpage>CD000542</fpage>.</citation>
</ref>
<ref id="bibr7-0884533613487218">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ordás</surname><given-names>I</given-names></name>
<name><surname>Feagan</surname><given-names>BG</given-names></name>
<name><surname>Sandborn</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change</article-title>. <source>Gut</source>. <year>2011</year>;<volume>60</volume>:<fpage>1754</fpage>-<lpage>1763</lpage>.</citation>
</ref>
<ref id="bibr8-0884533613487218">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alhagamhmad</surname><given-names>MH</given-names></name>
<name><surname>Day</surname><given-names>AS</given-names></name>
<name><surname>Lemberg</surname><given-names>DA</given-names></name>
<name><surname>Leach</surname><given-names>ST</given-names></name>
</person-group>. <article-title>An update of the role of nutritional therapy in the management of Crohn’s disease</article-title>. <source>J Gastroenterol</source>. <year>2012</year>;<volume>47</volume>:<fpage>872</fpage>-<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr9-0884533613487218">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goh</surname><given-names>J</given-names></name>
<name><surname>O’Morain</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Review article: nutrition and adult inflammatory bowel disease</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2003</year>;<volume>17</volume>:<fpage>307</fpage>-<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr10-0884533613487218">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takagi</surname><given-names>S</given-names></name>
<name><surname>Utsunomiya</surname><given-names>K</given-names></name>
<name><surname>Kuriyama</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Quality of life of patients and medical cost of “half elemental diet” as maintenance therapy for Crohn’s disease: secondary outcomes of a randomised controlled trial</article-title>. <source>Dig Liver Dis</source>. <year>2009</year>;<volume>41</volume>:<fpage>390</fpage>-<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr11-0884533613487218">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Afzal</surname><given-names>NA</given-names></name>
<name><surname>Van Der Zaag-Loonen</surname><given-names>HJ</given-names></name>
<name><surname>Arnaud-Battandier</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Improvement in quality of life of children with acute Crohn’s disease does not parallel mucosal healing after treatment with exclusive enteral nutrition</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2004</year>;<volume>20</volume>:<fpage>167</fpage>-<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr12-0884533613487218">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Assche</surname><given-names>G</given-names></name>
<name><surname>Dignass</surname><given-names>A</given-names></name>
<name><surname>Panes</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis</article-title>. <source>J Crohns Colitis</source>. <year>2010</year>;<volume>4</volume>:<fpage>7</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr13-0884533613487218">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Nutritional therapy for active Crohn’s disease</article-title>. <source>World J Gastroenterol</source>. <year>2008</year>;<volume>14</volume>:<fpage>4420</fpage>-<lpage>4423</lpage>.</citation>
</ref>
<ref id="bibr14-0884533613487218">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irvine</surname><given-names>EJ</given-names></name>
<name><surname>Feagan</surname><given-names>B</given-names></name>
<name><surname>Rochon</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group</article-title>. <source>Gastroenterology</source>. <year>1994</year>;<volume>106</volume>:<fpage>287</fpage>-<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr15-0884533613487218">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guyatt</surname><given-names>G</given-names></name>
<name><surname>Mitchell</surname><given-names>A</given-names></name>
<name><surname>Irvine</surname><given-names>EJ</given-names></name><etal/>
</person-group>. <article-title>A new measure of health status for clinical trials in inflammatory bowel disease</article-title>. <source>Gastroenterology</source>. <year>1989</year>;<volume>96</volume>:<fpage>804</fpage>-<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr16-0884533613487218">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irvine</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1999</year>;<volume>28</volume>:<fpage>S23</fpage>-<lpage>S27</lpage>.</citation>
</ref>
<ref id="bibr17-0884533613487218">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>SC</given-names></name>
<name><surname>Plamondon</surname><given-names>S</given-names></name>
<name><surname>Gupta</surname><given-names>A</given-names></name>
<name><surname>Burling</surname><given-names>D</given-names></name>
<name><surname>Kamm</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Prospective assessment of the effect on quality of life of anti–tumour necrosis factor therapy for perineal Crohn’s fistulas</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2009</year>;<volume>30</volume>:<fpage>757</fpage>-<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr18-0884533613487218">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lochs</surname><given-names>H</given-names></name>
<name><surname>Steinhardt</surname><given-names>HJ</given-names></name>
<name><surname>Klaus-Wentz</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Comparison of enteral nutrition and drug treatment in active Crohn’s disease: results of the European Cooperative Crohn’s Disease Study IV</article-title>. <source>Gastroenterology</source>. <year>1991</year>;<volume>101</volume>:<fpage>881</fpage>-<lpage>888</lpage>.</citation>
</ref>
<ref id="bibr19-0884533613487218">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malchow</surname><given-names>H</given-names></name>
<name><surname>Steinhardt</surname><given-names>HJ</given-names></name>
<name><surname>Lorenz-Meyer</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn’s disease. European Cooperative Crohn’s Disease Study III</article-title>. <source>Scand J Gastroenterol</source>. <year>1990</year>;<volume>25</volume>:<fpage>235</fpage>-<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr20-0884533613487218">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonzalez-Huix</surname><given-names>F</given-names></name>
<name><surname>de Leon</surname><given-names>R</given-names></name>
<name><surname>Fernandez-Banares</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Polymeric enteral diets as primary treatment of active Crohn’s disease: a prospective steroid controlled trial</article-title>. <source>Gut</source>. <year>1993</year>;<volume>34</volume>:<fpage>778</fpage>-<lpage>782</lpage>.</citation>
</ref>
<ref id="bibr21-0884533613487218">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorard</surname><given-names>DA</given-names></name>
<name><surname>Hunt</surname><given-names>JB</given-names></name>
<name><surname>Payne-James</surname><given-names>JJ</given-names></name><etal/>
</person-group>. <article-title>Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone</article-title>. <source>Gut</source>. <year>1993</year>;<volume>34</volume>:<fpage>1198</fpage>-<lpage>1202</lpage>.</citation>
</ref>
<ref id="bibr22-0884533613487218">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teahon</surname><given-names>K</given-names></name>
<name><surname>Bjarnason</surname><given-names>I</given-names></name>
<name><surname>Perason</surname><given-names>M</given-names></name>
<name><surname>Levi</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Ten years’ experience with an elemental diet in the management of Crohn’s disease</article-title>. <source>Gut</source>. <year>1990</year>;<volume>31</volume>:<fpage>1133</fpage>-<lpage>1137</lpage>.</citation>
</ref>
<ref id="bibr23-0884533613487218">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mahid</surname><given-names>SS</given-names></name>
<name><surname>Minor</surname><given-names>KS</given-names></name>
<name><surname>Soto</surname><given-names>RE</given-names></name>
<name><surname>Hornung</surname><given-names>CA</given-names></name>
<name><surname>Galandiuk</surname><given-names>S</given-names></name>
</person-group>. <article-title>Smoking and inflammatory bowel disease: a meta-analysis</article-title>. <source>Mayo Clin Proc</source>. <year>2006</year>;<volume>81</volume>:<fpage>1462</fpage>-<lpage>1471</lpage>.</citation>
</ref>
<ref id="bibr24-0884533613487218">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cottone</surname><given-names>M</given-names></name>
<name><surname>Rosselli</surname><given-names>M</given-names></name>
<name><surname>Orlando</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Smoking habits and recurrence in Crohn’s disease</article-title>. <source>Gastroenterology</source>. <year>1994</year>;<volume>106</volume>:<fpage>643</fpage>-<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr25-0884533613487218">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hommes</surname><given-names>D</given-names></name>
<name><surname>Colombel</surname><given-names>JF</given-names></name>
<name><surname>Emery</surname><given-names>P</given-names></name>
<name><surname>Greco</surname><given-names>M</given-names></name>
<name><surname>Sandborn</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life</article-title>. <source>J Crohns Colitis</source>. <year>2012</year>;<volume>6</volume>(<supplement>suppl 2</supplement>):<fpage>S224</fpage>-<lpage>S234</lpage>.</citation>
</ref>
<ref id="bibr26-0884533613487218">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>O</given-names></name>
<name><surname>Ando</surname><given-names>T</given-names></name>
<name><surname>Ishiguro</surname><given-names>K</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<name><surname>Ishikawa</surname><given-names>D</given-names></name>
<name><surname>Miyake</surname><given-names>N</given-names></name>
</person-group>. <article-title>Enteral nutrition decreases hospitalization rate in patients with Crohn’s disease</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2010</year>;<volume>25</volume>:<fpage>S134</fpage>-<lpage>S137</lpage>.</citation>
</ref>
<ref id="bibr27-0884533613487218">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irvine</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Quality of life issues in patients with inflammatory bowel disease</article-title>. <source>Am J Gastroenterol</source>. <year>1997</year>;<volume>92</volume>:<fpage>18S</fpage>-<lpage>24S</lpage>.</citation>
</ref>
<ref id="bibr28-0884533613487218">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irvine</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Quality of life in inflammatory bowel disease: biases and other factors affecting scores</article-title>. <source>Scand J Gastroenterol Suppl</source>. <year>1995</year>;<volume>208</volume>:<fpage>136</fpage>-<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr29-0884533613487218">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dupont</surname><given-names>B</given-names></name>
<name><surname>Dupont</surname><given-names>C</given-names></name>
<name><surname>Justum</surname><given-names>AM</given-names></name>
<name><surname>Piquet</surname><given-names>MA</given-names></name>
<name><surname>Reimund</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Enteral nutrition in adult Crohn’s disease: present status and perspectives</article-title>. <source>Mol Nutr Food Res</source>. <year>2008</year>;<volume>52</volume>:<fpage>875</fpage>-<lpage>884</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>